Current Report Filing (8-k)
January 06 2015 - 1:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 31, 2014
Bio-Matrix
Scientific Group, Inc.
(Exact
Name of Company as Specified in Charter)
|
|
|
Delaware |
0-32201 |
33-0824714 |
(State
or Other Jurisdiction of
Incorporation) |
(Commission
File Number) |
(IRS
Employer Identification
Number) |
4700
Spring Street, St 304
La
Mesa California, 91942
(Address
of Principal Executive Offices, Zip Code)
Company’s
telephone number, including area code: (619)
702-1404
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01
On
December 31, 2014 United States Patent Application No. 14588374 pertaining to the use of molecular interventions to treat myelodysplastic
syndrome was filed by Dr. Christine Ichim.
United
States Patent Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was
assigned to Regen BioPharma, Inc., (“Regen”) by Dr. Ichim on November 20, 2014. In addition all right, title and interest
in and to the invention covered by United States Patent Application No. 14588374 is assigned to Regen by Dr. Ichim pursuant to
the November 20, 2014 assignment as Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application
Serial Number 13/652,395.
On
December 31, 2014 United States Patent Application No. 14588373 pertaining to the suppression of the nuclear receptor NR2F2 using
compositions that induce RNA interference for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors
was filed by Dr. Christine Ichim.
United
States Patent Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was
assigned to Regen BioPharma, Inc. by Dr. Ichim on November 20, 2014. In addition all right, title and interest in and to the invention
covered by United States Patent Application No. 14588373 is assigned to Regen by Dr. Ichim pursuant to the November 20, 2014 assignment
as Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
Regen
is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc.
Item
9.01 Exhibits.
Exhibit
No. |
|
Description
of Exhibit |
10.1 |
|
Assignment
( incorporated by reference to Exhibit 10.33 of Bio- Matrix Scientific Group Inc.’s Form 10-K filed December
29, 2014) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Bio- Matrix
Scientific Group, Inc. |
|
|
Dated: January 6, 2015 |
By: /s/
David Koos |
|
David Koos |
|
Chief Executive Officer |